THE TAPE
SNDX · Pharmaceutical Preparations · $815.3M

Syndax Pharmaceuticals, Inc.

$9.13▼ −3.39%
Last close
Relative strength
2RS
of 99, against every stock▼ -2 on the month
Falling back
Unconfirmed
−57.6%
six months against Pharmaceutical Preparations
52-week range
−64.3%
from the high
$9.06$25.59
Setup
blue skyplayed out
−59.8%
against the pivot at $22.73
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +82% on a year ago
11/16 O 9.34 H 9.47 L 9.06 Vol 2.5M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS2
vs pivot−59.83%
Tightening0.98×
Dry-up0.96×
Up/down vol-0.29
From high64%
played out0 of 9checks
Falling back
Support and resistance

No price has been tested three times in the last 120 sessions: it has not spent long enough in one range to form a level.

The read

The base has run 10.0 weeks and fell 15% from its ceiling at its deepest. The pivot is $22.73, and the stock closed 59.8% below it. Its relative strength rating is 2.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-32.2%
Three months against its industry
-47.0%
Six months against its industry
-57.6%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 11.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$289.7M
+81.6% year on year
Operating margin
-61.7%
Net margin
-72.3%
Free cash flow
$-177.4M
-21.8% of market cap
Price to sales
2.81×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 2
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$83.3M
+14.4% QoQ · +81.6% YoY
Gross margin
—
Net income
−$49.4M
Loss
Free cash flow
−$27.3M
Burning · 5q runway

What the numbers say

  • Good: Revenue +81.6% year over year, +14.4% on the quarter
  • Weak: Net loss $49M, wider than $49M last quarter
  • Weak: Burning cash: operating cash flow -$27M, free cash flow -$27M, better than -$30M last quarter · 5 quarters of cash at this burn
  • Weak: Net debt $214M · cash $136M
Revenue by quarter
Free cash flow
Net income
shares +3.7% in a year · net debt $214.1M

What is not obvious

  • Weak: Stock compensation $15M added back against negative operating cash flow
  • Weak: Interest $2K a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $49M, wider than $49M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

No tracked fund holds it now at the end of Q3 2026.

Last quarter: 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-06
-10.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week lowTape · 2026-11-05
5.8x vol
Mixed: stocks have outrun random stocks by 0.6% over three sessions, not consistently enough to call (746 cases over 51 nights). Against their own sector they have outrun by 0.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-05
below 20d & 50d on 5.8x volume at 10.45
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-05
-26.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-05
9.8 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-04
+9.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-04
+9.1% on earnings 2026-11-02
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
A director or officer changedFiling · 2026-11-03
2.02,5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
6
$2,234,511 total

Sold: Podlesak Dennis, Metzger Michael A, Botwood Nicholas A.J., Goldan Keith A..

Not counted above: 4 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-29 Podlesak Dennis · Directoroption exercise8,000$94,480
2026-10-29 Podlesak Dennis · Directorsell8,000$113,716
2026-07-08 Metzger Michael A · Chief Executive Officer, Directoroption exercise32,375$206,553
2026-07-08 Metzger Michael A · Chief Executive Officer, Directorsell32,375$784,776
2026-06-12 Botwood Nicholas A.J. · Head of R&D, CMOoption exercise31,235$431,668
2026-06-12 Botwood Nicholas A.J. · Head of R&D, CMOsell31,235$566,603
2026-06-11 Botwood Nicholas A.J. · Head of R&D, CMOoption exercise22,515$311,157
2026-06-11 Botwood Nicholas A.J. · Head of R&D, CMOsell34,280$617,040

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

0 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy2
Buy10
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Syndax Pharmaceuticals, Inc. (SNDX) — The Tape